<DOC>
	<DOCNO>NCT01191996</DOCNO>
	<brief_summary>The purpose study determine safety tolerability , dose-limiting toxicity , maximum tolerate dose , recommend therapeutic dose intravenously administer MIS416 weekly patient chronic progressive multiple sclerosis .</brief_summary>
	<brief_title>Safety Study Immunomodulating Microparticle Treat Progressive Multiple Sclerosis</brief_title>
	<detailed_description>This single center , open-label , non-randomized , dose-escalation study , conduct two phase : - dose-escalation ( DE ) phase , evaluate safety , tolerability , MTD , PD MIS416 administer IV weekly 4 dos ; - dose-confirmation ( DC ) phase , cohort expansion MTD ( i.e. , RTD ) MIS416 , dose weekly 12 dos . Subjects treat weekly IV dose MIS416 28-day cycle : 1 cycle DE phase , 3 cycle DC phase . Subjects evaluate dosed weekly cycle phase . Subjects return follow-up visit 7 day completion last dose study drug . The primary objective study : 1 . To determine safety tolerability , dose-limiting toxicity ( DLTs ) , maximum tolerate dose ( MTD ) , recommend therapeutic dose ( RTD ) intravenously ( IV ) administer MIS416 weekly patient chronic progressive multiple sclerosis ( CPMS ) ; 2 . To assess pharmacodynamic ( PD ) effect MIS416 , include effect serum cytokine level peripheral blood mononuclear cell ( PBMC ) composition , cytokine/chemokine expression function . The secondary objective study : 1 . To document change MS clinical status occur 12-week MIS416 dose period dose-confirmation phase , determine Multiple Sclerosis Functional Composite ( MSFC ) , Fatigue Severity Scale ( FSS ) , Short Form Health Survey ( SF-36 ) , Expanded Disability Status Scale ( EDSS ) ; frequency clinical relapse ; sign clinical activity serial cranial MRI scan ; 2 . To evaluate , exploratory fashion , correlation clinical , radiological PD outcome .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>At least 18 year age . Diagnosis MS , McDonald criterion . Chronic progressive MS ( CPMS ) , define either primary progressive MS ( PPMS ) secondary progressive MS ( SPMS ) , per criterion National Multiple Sclerosis Society ( USA ) Advisory Committee Clinical Trials New Agents Multiple Sclerosis . [ NOTE : In doseconfirmation phase , subject SPMS may enrol ] . MS clinically active worsen clinical status within past 2 year , define increase EDSS 1 point , sustain least 6 month . Expanded Disability Status Scale ( EDSS ) 2.5 7.0 Screening . The following laboratory value must document within 3 day prior initiation study drug : Absolute neutrophil count ( ANC ) &gt; = 1 x 109/L Platelet count &gt; = 100 x 109/L Serum creatinine = &lt; 1.5 mg/dL AST ( SGOT ) ALT ( SGPT ) = &lt; 2 × upper limit normal . Provide write informed consent participate . Relapsingremitting MS progressiverelapsing MS Any immunomodulatory drug therapy immunosuppressive therapy within previous six month , vaccine systemic corticosteroid within previous 60 day , prior initiation study drug . Exposure experimental treatment currently investigation MS clinical trial , include alemtuzamab , rituximab , fingolimod , clabribine . A diagnosis history collagen vascular disease ( include Sjögren 's syndrome systemic lupus erythematosus ) , anticardiolipin antibody syndrome , cerebral autosomal dominant arteriopathy subcortical infarct leukoencephalopathy ( CADASIL ) , sarcoidosis , vasculitis , Bechet 's syndrome and/or Lyme disease . History alcohol drug abuse ( exception cannabinoids ) within 2 year prior initiation study drug . Previous exposure MIS416 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>SPMS</keyword>
	<keyword>PPMS</keyword>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>